IL2 and systemic lupus erythematosus: LD‐IL‐2 therapy induces the proliferation and functional recovery of Treg cells and inhibits the differentiation of Th17 and T follicular helper(Tfh) cells in patients with SLE, thereby reducing disease activity and restoring immune homeostasis.